Compare JPMorgan Chase & Co (JPM) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Neurocrine Biosciences Inc — how do they compare? JPMorgan Chase & Co trades at $332.4 (market cap $876.09B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: JPMorgan Chase & Co is far larger — about 60× Neurocrine Biosciences Inc's market cap, and JPMorgan Chase & Co pays a 2% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Chase & Co for 127 Days and Neurocrine Biosciences Inc for 23 Days on average.
| JPM | NBIX | |
|---|---|---|
Market Cap | $876.09B | $14.60B |
Volume | 6,651,143 | 1,075,694 |
Sector | Financials | Health |
52-Week High | $365.18 | $185.50 |
52-Week Low | $282.84 | $123.10 |
Typical Hold Time | 127 Days | 23 Days |
Enterprise Value | $1.81T | $14.61B |
Dividend Yield | 2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $329.58, down 0.51% on the day, with a bearish technical signal. The stock shows strong fundamentals, with a P/E of 14.12 and net income margin of 33.38%. Recent earnings beat expectations in Q1 and Q2 2026, though Q4 2025 was a miss. Analyst consensus is a Moderate Buy with a $373.18 price target, implying potential upside. Cash flow trends show significant financing activities offsetting negative operating cash flows.
The outlook for JPM is positive based on robust profitability and analyst support, but risks include volatile cash flows, geopolitical tensions affecting banking sectors, and CEO warnings on economic challenges. The stock's current price near support at $327 suggests a potential entry point for long-term investors, though near-term bearish technicals warrant caution.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
